top of page
Neurotez Inc.
Login to favorite a company
Neurotez Inc. is developing a drug to treat Leptin deficiency in Alzheimer’s patients.
Most Recent Valuation:
$45,272,228.00
Legal Name:
Founded:
State of HQ:
Neurotez Inc.
10/14/2005
NJ
Company Description
Employees:
[]
Funding Summary
Number of funding rounds
4
Total amount raised
$305,811
Round name | End date | Raised | Status | Type | Investment minimum | Valuation | Valuation Cap | Price per share |
|---|---|---|---|---|---|---|---|---|
Neurotez Inc. Common Stock 4 | 01/27/2023 | $15,952.00 | closed | Common Stock | $100 | $45,272,228 | 4 | |
Neurotez Common Stock 3 | 03/11/2022 | $33,845.00 | closed | Common Stock | $496 | $44,900,000 | 4 | |
Neurotez, Inc. Stock 2 | 06/24/2021 | $256,014.00 | closed | Common Stock | $2 | $22,030,500 | 2 | |
Neurotez, Inc. Stock 1 | closed | Common Stock | 1 |
See round history
Round history
Round name | Perk description | Perk level (dollars) | Perk level (days) |
|---|
Loading...
Early Bird Perk history
Company notes
Type | Round name | Date Added | Date Updated | Notes |
|---|
Loading...
Financials (up to prior 4 years)
Revenue
COGS
Gross margin | (%)
Taxes
SG&A, other
Net income
Cash/Equivalents
Accounts Receiv
Other Assets
Assets
Short term debt
Long term debt
Equity/other liabilities
Gross margin, Other Assets, and Equity/other liabilities are derived from the financial statements of the company reported to the SEC. Assets = Liabilities + Equity, and no equity accounts nor accounts payable are reported to the SEC, hence the possibility for that amount to be either equity or a liability.
bottom of page